A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Enanta Pharmaceuticals, Inc. made the strategic decision to discontinue the ARGON-2 study to prioritize combination treatment approaches. This decision was not based on safety concerns.

Conditions

Non-Alcoholic Steatohepatitis

Interventions

DRUG: EDP-305 1.5 mg
DRUG: EDP-305 2 mg
DRUG: Placebo

Sponsor

Enanta Pharmaceuticals, Inc